Search
Pipotiazine
go.drugbank.com/drugs/DB01621ApprovedInvestigationalWithdrawnPipotiazine has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depr...
Doripenem
go.drugbank.com/drugs/DB06211ApprovedWithdrawnDoripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. In a clinical t...
Leronlimab
go.drugbank.com/drugs/DB05941InvestigationalLeronlimab, or PRO-140, is a human monoclonal antibody developed by CytoDyn. It was first described in the literature in 2001. This antibody binds to CCR5, which may be useful in treating HIV, cancers, and severely ill COVID-19 patients.
NRP409
go.drugbank.com/drugs/DB05235ExperimentalNRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.
Voclosporin
go.drugbank.com/drugs/DB11693ApprovedInvestigational[A227683] Voclosporin, marketed as Lupkynis, is a calcineurin-inhibitor immunosuppressant for the treatment of LN.
Zinc dibutyldithiocarbamate
go.drugbank.com/drugs/DB14194ApprovedZinc dibutyldithiocarbamate is a dermatological sensitizer and allergen. Sensitivity to zinc dibutyldithiocarbamate may be identified with a clinical patch test.
Mepenzolate
go.drugbank.com/drugs/DB04843ApprovedWithdrawnMepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also s...
Amolimogene bepiplasmid
go.drugbank.com/drugs/DB04904InvestigationalAmolimogene was biologically engineered as a targeted therapy for the treatment of cervical dysplasia.
Gimeracil
go.drugbank.com/drugs/DB09257ApprovedInvestigationalGimeracil is an adjunct to antineoplastic therapy, used to increase the concentration and effect of the main active componets within chemotherapy regimens. Approved by the European Medicines Agency (EMA) in March 2011, Gimeracil is avail...